2011 - German National Academy of Sciences Leopoldina - Deutsche Akademie der Naturforscher Leopoldina – Nationale Akademie der Wissenschaften Internal Medicine and Dermatology
His primary areas of investigation include Internal medicine, Chronic lymphocytic leukemia, Fludarabine, Surgery and Immunology. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Oncology. In his research, Bioinformatics, Mutation, Cancer research and Lung cancer is intimately related to Cancer, which falls under the overarching field of Oncology.
His Chronic lymphocytic leukemia study improves the overall literature in Leukemia. His work focuses on many connections between Fludarabine and other disciplines, such as Bendamustine, that overlap with his field of interest in Refractory Chronic Lymphocytic Leukemia. Michael Hallek works mostly in the field of Immunology, limiting it down to topics relating to Cytotoxic T cell and, in certain cases, FOXP3, Interleukin 2 and Cancer immunotherapy.
Michael Hallek mostly deals with Internal medicine, Chronic lymphocytic leukemia, Oncology, Immunology and Cancer research. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery. His Chronic lymphocytic leukemia study results in a more complete grasp of Leukemia.
He interconnects Venetoclax, Idelalisib, Obinutuzumab and Transplantation in the investigation of issues within Oncology. His research in Cancer research intersects with topics in Apoptosis, breakpoint cluster region, Tyrosine kinase and CD40. His study in Fludarabine is interdisciplinary in nature, drawing from both Regimen, Alemtuzumab, Progression-free survival and [email protected]
His primary scientific interests are in Internal medicine, Chronic lymphocytic leukemia, Oncology, Venetoclax and Cancer research. His Obinutuzumab, Rituximab, Ibrutinib and Chemoimmunotherapy study in the realm of Internal medicine connects with subjects such as In patient. In his study, which falls under the umbrella issue of Chronic lymphocytic leukemia, Neutropenia is strongly linked to Gastroenterology.
His studies in Oncology integrate themes in fields like Idelalisib, Clinical trial, Chemotherapy, Stage and Comorbidity. His work deals with themes such as Progression-free survival and Tumor lysis syndrome, which intersect with Venetoclax. Michael Hallek has included themes like Cancer, Phenotype, Tyrosine kinase, B cell and Monoclonal antibody in his Cancer research study.
Michael Hallek mainly focuses on Internal medicine, Chronic lymphocytic leukemia, Oncology, Venetoclax and Cancer research. As part of his studies on Internal medicine, he often connects relevant areas like Gastroenterology. He combines subjects such as MEDLINE and Minimal residual disease with his study of Chronic lymphocytic leukemia.
His Oncology research includes elements of Cancer, Chemotherapy, Chemoimmunotherapy, [email protected] and Stage. His research investigates the connection between Venetoclax and topics such as Progression-free survival that intersect with problems in Randomized controlled trial and Hazard ratio. His Cancer research research incorporates elements of Cell culture, Autocrine signalling and B-cell receptor, B cell.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;Anne Michelle Fink.
The Lancet (2010)
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson.
The New England Journal of Medicine (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede;Kirsten Fischer;Raymonde Busch;Anja Engelke.
The New England Journal of Medicine (2014)
Comprehensive genomic profiles of small cell lung cancer
Julie George;Jing Shan Lim;Se Jin Jang;Yupeng Cun.
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George.
Nature Genetics (2012)
Real-time single-molecule imaging of the infection pathway of an adeno-associated virus.
Georg Seisenberger;Martin U. Ried;Thomas Endreß;Hildegard Büning.
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
M Hallek;P L Bergsagel;K C Anderson.
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer.
Science Translational Medicine (2010)
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Barbara F. Eichhorst;Raymonde Busch;Georg Hopfinger;Rita Pasold.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: